82 research outputs found
Association of the Hermansky-Pudlak syndrome type-3 protein with clathrin
BACKGROUND: Hermansky-Pudlak syndrome (HPS) is a disorder of lysosome-related organelle biogenesis characterized by oculocutaneous albinism and prolonged bleeding. These clinical findings reflect defects in the formation of melanosomes in melanocytes and dense bodies in platelets. HPS type-3 (HPS-3) results from mutations in the HPS3 gene, which encodes a 1004 amino acid protein of unknown function that contains a predicted clathrin-binding motif (LLDFE) at residues 172–176. RESULTS: Clathrin was co-immunoprecipitated by HPS3 antibodies from normal but not HPS3 null melanocytes. Normal melanocytes expressing a GFP-HPS3 fusion protein demonstrated partial co-localization of GFP-HPS3 with clathrin following a 20°C temperature block. GFP-HPS3 in which the predicted clathrin-binding domain of HPS3 was mutated (GFP-HPS3-delCBD) did not co-localize with clathrin under the same conditions. Immunoelectron microscopy of normal melanocytes expressing GFP-HPS3 showed co-localization of GFP-HPS3 with clathrin, predominantly on small vesicles in the perinuclear region. In contrast, GFP-HPS3-delCBD did not co-localize with clathrin and exhibited a largely cytoplasmic distribution. CONCLUSION: HPS3 associates with clathrin, predominantly on small clathrin-containing vesicles in the perinuclear region. This association most likely occurs directly via a functional clathrin-binding domain in HPS3. These results suggest a role for HPS3 and its protein complex, BLOC-2, in vesicle formation and trafficking
Two Novel Mutations Identified in an African-American Child with Chediak-Higashi Syndrome
Background. Chediak-Higashi syndrome (CHS) is a rare, autosomal recessive disorder characterized by oculocutaneous albinism, immunodeficiency, coagulopathy and late-onset, progressive neurological dysfunction. It also has an “accelerated phase” characterized by hemophagocytic lymphohistiocytosis (HLH). The disease is caused by mutations in the CHS1/LYST gene located on chromosome 1, which affects lysosome morphology and function. We report the case of an African-American child with CHS in Case. This 16-month old African-American girl presented with fever and lethargy. The proband had pale skin compared to her parents, with light brown eyes, silvery hair and massive hepatosplenomegaly. Her laboratory evaluation was remarkable for pancytopenia, high serum ferritin and an elevated LDH. Bone marrow aspirate revealed large inclusions in granulocytes and erythrophagocytosis consistent with HLH. Genetic evaluation revealed two novel nonsense mutations in the CHS1 gene: c.3622C > T (p.Q1208X) and c.11002G > T (p.E3668X). Conclusions. Our patient is one of the few cases of CHS reported in the African American population. We identified 2 nonsense mutations in the CHS1 gene, the first mutation analysis published of an African-American child with Chediak-Higashi Syndrome. These two mutations predict a severe phenotype and thus identification of these mutations has an important clinical significance in CHS
Intravenous immune globulin in hereditary inclusion body myopathy: a pilot study
BACKGROUND: Hereditary Inclusion Body Myopathy (HIBM) is an autosomal recessive, adult onset, non-inflammatory neuromuscular disorder with no effective treatment. The causative gene, GNE, codes for UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase, which catalyzes the first two reactions in the synthesis of sialic acid. Reduced sialylation of muscle glycoproteins, such as α-dystroglycan and neural cell adhesion molecule (NCAM), has been reported in HIBM. METHODS: We treated 4 HIBM patients with intravenous immune globulin (IVIG), in order to provide sialic acid, because IgG contains 8 μmol of sialic acid/g. IVIG was infused as a loading dose of 1 g/kg on two consecutive days followed by 3 doses of 400 mg/kg at weekly intervals. RESULTS: For all four patients, mean quadriceps strength improved from 19.0 kg at baseline to 23.2 kg (+22%) directly after IVIG loading to 25.6 kg (+35%) at the end of the study. Mean shoulder strength improved from 4.1 kg at baseline to 5.9 kg (+44%) directly after IVIG loading to 6.0 kg (+46%) at the end of the study. The composite improvement for 8 other muscle groups was 5% after the initial loading and 19% by the end of the study. Esophageal motility and lingual strength improved in the patients with abnormal barium swallows. Objective measures of functional improvement gave variable results, but the patients experienced improvements in daily activities that they considered clinically significant. Immunohistochemical staining and immunoblotting of muscle biopsies for α-dystroglycan and NCAM did not provide consistent evidence for increased sialylation after IVIG treatment. Side effects were limited to transient headaches and vomiting. CONCLUSION: The mild benefits in muscle strength experienced by HIBM patients after IVIG treatment may be related to the provision of sialic acid supplied by IVIG. Other sources of sialic acid are being explored as treatment options for HIBM
Biobanking for Viral Hepatitis Research
Introduction: Viral hepatitis is a worldwide, important health issue. The optimal
management of viral hepatitis infections faces numerous challenges. In this paper, we
describe how biobanking of biological samples derived from viral hepatitis patients
collected both in-hospital and during community outreach screenings provides a unique
collection of samples.
Materials and Methods: All samples and materials were provided with a study code
within the SLIMS system Study protocols and an informed consent form were approved
by the Antwerp University Hospital/University of Antwerp Ethical Committee. Systematic
biobanking was initiated in October 2014. Collected sample types include: (1) serum and
plasma of all newly diagnosed HBV, HCV, HDV, and HEV positive patients; (2) left-over
serum and plasma samples from all PCR analyses for HBV and HCV performed in the
context of routine clinical care; (3) left-over liver tissue not needed for routine histological
diagnosis after liver biopsy; and (4) additional virus-specific, appropriate sample types
using a scientific rationale-based approach. A community outreach screening program
was performed in three major Belgian cities. Serum, EDTA, Tempus Blood RNA and BD
Vacutainer CPT were collected. CPT tubes were centrifuged on-site and mononuclear
cells collected within 24 h.
Results: Concerning community screening: 298 individuals supplied all 4 sample types.
Samples were stored at −150◦C and were logged in the biobank SLIMS database.
Samples were used for HBV-related immunological and biomarker studies. DNA isolated
from plasma samples derived from chronic HBV patients was used to investigate
Single Nucleotide Polymorphism rs 1790008. Serum samples collected from chronic
hepatitis C patients were used to assess the efficacy of HCV treatment. Peripheral Blood
Mononuclear Cells (PBMC) isolated from chronic HBV patients and healthy controls were
used for different immunological study purposes. Virus isolated from biobanked stool of a
chronic hepatitis E patient was used to establish a mouse model for Hepatitis E infections,
allowing further HEV virology studies.
Conclusion: The establishment of a biobank with samples collected both in-hospital
and during community-outreach screening resulted in a unique, continuously expanding
collection of biological samples which provides an excellent platform for prompt answers
to clinically and translational relevant research questions
Case Report Two Novel Mutations Identified in an African-American Child with Chediak-Higashi Syndrome
Seeking the biochemical basis of type III 3-methylglutaconic aciduria through zebrafish models
- …